menu
    • menu

    Company profile for Kineta

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Kineta, Inc. is a clinical stage biotechnology company committed to developing disruptive life science technologies that address unmet patient needs. We have leveraged our expertise in immunology to advance a focused pipeline of investigational drugs in oncology, neuroscience and biodefense. We actively collaborate with a broad array of industry, government and academic partners to advance our innovative research.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    KinetaUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    219 Terry Ave., N Suite 300 Seattle, WA 98109
    Telephone
    Telephone
    206.378.0400
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://kinetabio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/kineta-inc-/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/kinetabio

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    TuHURA Biosciences Completes Acquisition of Kineta
    TuHURA Biosciences Completes Acquisition of Kineta

    30 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/tuhura-biosciences-completes-acquisition-of-kineta-302494115.html

    PR NEWSWIRE
    30 Jun 2025
    Share Share
    TuHURA Biosciences, Kineta Stockholders Approve Merger
    TuHURA Biosciences, Kineta Stockholders Approve Merger

    23 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/tuhura-biosciences-inc-and-kineta-inc-stockholders-approve-proposed-merger-and-all-related-proposals-302488460.html

    PR NEWSWIRE
    23 Jun 2025
    Share Share
    TuHURA Biosciences & Kineta Present Updated Results at AACR Meeting
    TuHURA Biosciences & Kineta Present Updated Results at AACR Meeting

    28 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/tuhura-biosciences-and-kineta-present-updated-results-from-kinetas-phase-i-ii-study-of-kva12123-and-tuhuras-mechanism-of-ifx-hu2-0-responses-after-anti-pd-1-therapy-failure-in-advanced-melanoma-at-the-american-association-for-ca-302439358.html

    PR NEWSWIRE
    28 Apr 2025
    Share Share
    Kineta sells Genentech, Merck deals to investor ahead of merger
    Kineta sells Genentech, Merck deals to investor ahead of merger

    11 Feb 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/kineta-sells-genentech-and-merck-deals-investor-ahead-tuhura-merger

    FIERCE BIOTECH
    11 Feb 2025
    Share Share
    Kineta Updates KVA12123 Phase 1/2 Data at SITC 2024
    Kineta Updates KVA12123 Phase 1/2 Data at SITC 2024

    08 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/08/2977670/0/en/Kineta-Updates-KVA12123-Clinical-Results-from-Ongoing-Phase-1-2-VISTA101-Study-at-Society-for-Immunotherapy-of-Cancer-2024.html

    GLOBENEWSWIRE
    08 Nov 2024
    Share Share
    Kineta Completes Enrollment In VISTA-101 Ph 1 Study For Solid Tumors
    Kineta Completes Enrollment In VISTA-101 Ph 1 Study For Solid Tumors

    08 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/en/news-release/2024/10/08/2959766/0/en/Kineta-Announces-Completion-of-Enrollment-in-the-Monotherapy-Arm-of-the-VISTA-101-Phase-1-Clinical-Study-in-Advanced-Solid-Tumors.html

    GLOBENEWSWIRE
    08 Oct 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search